Body mass index affects imatinib exposure
Author Information
Author(s): Maroselli Paul, Fanciullino Raphaelle, Colle Julien, Farnault Laure, Roche Pauline, Venton Geoffroy, Costello Régis, Ciccolini Joseph
Primary Institution: La Conception University Hospital of Marseille
Hypothesis
Does body mass index (BMI) influence imatinib pharmacokinetics in CML patients?
Conclusion
Low BMI significantly impacts imatinib exposure, but pharmacokinetically-guided dosing mitigates its clinical effects.
Supporting Evidence
- Only 29% of patients were in the therapeutic range for imatinib.
- Patients with BMI < 18.5 kg/m2 had significantly higher imatinib levels.
- Adaptive dosing was implemented for 74% of patients based on TDM results.
- No difference in toxicity or efficacy was observed after adaptive dosing.
- Mean trough levels were 994.2 ± 560.6 ng/ml at treatment initiation.
Takeaway
If you're small, the medicine might hit you harder, but doctors can adjust the dose to keep you safe.
Methodology
This was a retrospective, non‐interventional, observational study using therapeutic drug monitoring (TDM) and adaptive dosing in CML patients.
Potential Biases
Potential bias due to the retrospective nature and lack of longitudinal TDM after dose adjustments.
Limitations
The study was limited by the small sample size and the single-institution setting.
Participant Demographics
Mean age 56 years, 33 males and 27 females.
Statistical Information
P-Value
0.018
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website